Conclusions
Many different and evolving approaches are available for the treatment of ulcerative colitis. A comprehensive treatment that includes not just the disease but also the patient (often severely debilitated by a lifelong disease, in a proportion of cases refractory to standard treatments) and an effective patient-doctor alliance may improve the overall results.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 126:1504–1517
Longobardi T, Jacobs T, Wu L et al (2003) Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. Am J Gastroenterology 98:844–849
Card T, Hubbard R, Logan RFA (2003) Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125:1583–1590
Carter MJ, Lobo AJ Travis SPL (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53:v1–v16
Sutherland LR, May GR, Shaffer EA (1993) Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118:540–549
Sutherland L, Roth D, Beck P et al (2000) Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2:CD000543
Hanauer S, Schwartz J, Robinson M et al (1993) Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial: Pentasa Study Group. Am J Gastroenterol 88:1188–1197
Green JR, Lobo AJ, Holdsworth CD et al (1998) Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis: The Abacus Investigator Group. Gastroenterology 114:15–22
Kruis W, Brandes JW, Schreiber S et al (1998) Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 12:707–715
Miner P, Hanauer S, Robinson M et al (1995) Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis: Pentasa UC Maintenance Study Group. Dig Dis Sci 40:296–304
Hawkey CJ, Dube LM, Rountree LV et al (1997) A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis: The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112:718–724
Sandberg-Gertzen H, Jarnerot G, Kraaz W (1986) Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse-prevention properties. Gastroenterology 90:1024–1030
Wright JP, O’Keefe EA, Cuming L, Jaskiewicz K (1993) Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 38:1837–1842
Hanauer S, Sninsky C, Robinson M et al (1996) An oral preparation of mesalamine as longterm maintenance therapy for ulcerative colitis: a randomized, placebocontrolled trial. Ann Intern Med 124:204–211
Ardizzone S, Petrillo M, Imbesi V et al (1999) Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 13:373–379
Miner P, Hanauer S, Robinson M et al (1995) Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis: Pentasa UC Maintenance Study Group. Dig Dis Sci 40:296–304
Ngo Y, Gelinet JM, Ivanovic A et al (1992) Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis: a double-blind versus placebo randomized trial [In French]. Gastroenterol Clin Biol 16:782–786
Williams CN, Haber G, Aquino JA (1987) Doubleblind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc labeled 5-ASA suppositories. Dig Dis Sci 32:71S–75S
Campieri M, De Franchis R, Bianchi Porro G et al (1990) Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis: a randomized controlled trial. Scand J Gastroenterol 25:663–668
Campieri M, Gionchetti P, Belluzzi A et al (1990) Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation: a double-blind placebo controlled trial. Int J Colorectal Dis 5:79–81
Campieri M, Gionchetti P, Belluzzi A et al (1991) Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32:929–931
Sutherland LR, Martin F, Greer S et al (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898
Campieri M, Gionchetti P, Belluzzi A (1990) Sucralfate, 5-aminosalicylic acid, and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol Hepatol 3:41–44
Hanauer SB (1998) Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial: The US Pentasa Enema Study Group. Inflamm Bowel Dis 4:79–83
Marshall JK, Irvine EJ (1995) Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 9:293–300
Cohen RD, Woseth DM, Thisted RA, Hanauer SB (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterology 95:1263–1276
Kam L, Cohen H, Dooley C et al (1996) A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 91:1338–1342
Reddy SI, Friedmanm S, Telford JJ et al (2005) Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 100:1357–1361
Sachar DB (2003) Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis 9:205–209
Loftus EV, Kane SV, Bjorkman D (2004) Systemic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19:179–189
Ransford RAJ, Langman MJS (2002) Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51:536–539
Van Staa TP, Travis SPL, Leufkens HJM et al (2004) 5-aminosalicylic acids and the risk of renal disease: a large British epidemiological study. Gastroenterology 126:1733–1739
Rosenberg JL, Wall AJ, Levin B et al (1975) A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 69:96–99
Kirk AP, Lennard-Jones JE (1982) Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 284:1291–1292
Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50:485–489
Ardizzone S, Maconi G, Russo A et al (2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55:47–53
Mantzaris GJ, Archavlis E, Kourtessas D et al (2001) Oral azathioprine for steroid refractory severe ulcerative colitis. Am J Gastroenterol 96:2797–2808
Ardizzone S, Molteni F, Imbesi V et al (1997) Azathioprine in steroid resistant and steroid dependant ulcerative colitis. J Clin Gastroenterol 25:330–333
Lennard L, Gibson BE, Nicole T (1993) Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69:577–579
Colombel JF, Ferrari N, Debuysere H et al (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118:1025–1030
Sandborn WJ, Tremaine WJ, Wolf DC et al (1999) Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 117:527–535
The mycophenolate mofetil refractory rejection study group (1996) Mycophenolate mofetil for the treatment of refractory acute, cellular renal transplantation rejection. Transplantation 61:722–729
Farell RJ, Ang Y, Kileen P et al (2000) Increased incidence of non Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47:514–519
Connel WR, Kamm MA, Dickson MB et al (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249–1252
— (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 54:1121–1125
Fraser Ag, Jewell DP (2000) Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine: a 30 years study. Gastroenterology 118:A1471
Lewis JD, Bilker WB, Brensinger C et al (2001) Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121:1080–1087
Francella A, Dyan A, Bodian C et al (2003) The safety of 6 mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124:9–17
Stange EF, Neurath MF (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110:1416–1421
Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno Otero R (2000) 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 12:1227–1233
Morton D, McGovern D, Jewell DP (2002) The efficacy of methotrexate for maintaining remission in inflammatory bowel disease Aliment Pharmacol Ther 16:693–697
Te HS, Schiano TD, Kuan SF et al (2000) Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 95:3150–3156
Lichtiger S, Present DH, Kornbluth A et al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J of Med 330:1841–1845
D’Heans G, Lemmens L, Geboes K et al (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120:1323–1329
Svanoni F, Bonassi U, Bagnolo F et al (1998) Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC). Gastroenterology 114:A1096
Van Assche G, D’Haens G, Noman M et al (2003) Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125:1025–1031
Sandborn WJ, Tremaine WJ, Schroeder KW et al (1994) A placebo-controlled trial of cyclosporine enemas for mildly-moderate active left-sided ulcerative colitis. Gastroenterology 106:1429–1435
Travis SP, Farrant JM, Ricketts C et al (1996) Predicting outcome in ulcerative colitis. Gut 38:905–910
Lindgren SC, Flood LM, Kilander AF et al (1998) Early predictors of glucocorticoids treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10:831–835
Schibolet O, Regushevskaya E, Brezis M, Soares-Weise K (2005) Cyclosporin A for induction of remission in severe ulcerative colitis. The Cochrane Database of Systematic Review Issue 4
Sternthal M, George J, Kornbluth A et al (1996) Toxicity associated with the use of cyclosporine in patients with inflammatory bowel disease. Gastroenterology 110:A1019
De Groen PC, Aksamit AJ, Rakela J et al (1987) Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 317:861–866
Fellermann K, Ludwig D, Stahl M et al (1998) Steroidunresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860–1866
Baumgart DC, Wiedenmann B, Dignass AU (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 15:1273–1281
Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W (2003) Effect of oral tacrolimus on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 18:415–423
Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M (2002) Infliximab for treatment of steroidrefractory ulcerative colitis. Dig Liver Dis 34:631–634
Gornet Jm, Couve S, Hassani Z et al (2003) Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 18:175–181
Jarnerot G, Hertevig E, Friis-Liby I et al (2005) Infliximab as a rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811
Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476
Musch E, Andus T, Malek M (2002) Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis: an open long-term pilot trial. Aliment Pharmacol Ther 16:1233–1239
Nikolaus S, Rutgeerts P, Fedorak R (2003) Interferon b-1a in ulcerative colitis: a placebo-controlled, randomised, dose escalating study. Gut 52:1286–1290
Musch E, Andus T, Kruis W et al (2005) Interferon beta-1a for the treatment of steroid refractory ulcerative-colitis: a randomized double-blind placebo-controlled trial. Clin Gastroenterol Hepatol 3:581–586
Feagan BG, Greenberg GR, Wild G et al (2005) Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med 352:2499–2507
Danese S, De La Rue SA, Gasbarrini A (2005) Antibody to the α4β7 integrin. N Engl J Med 353:118
Kondo K, Shinoda T, Yoshimoto H (2001) Effective maintenance leukocytapheresis for patients with steroid dependent or resistant ulcerative colitis. Ther Apher 5:462–465
Sakata H, Kawamura N, Takashi H et al (2003) Successful treatment of ulcerative colitis with leukocytapheresis using non-woven polyester filter. Ther Apher Dial 7:536–539
Kanke K, Nakano M, Hiraishi H, Terano A (2004) Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 36:811–817
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Italia
About this chapter
Cite this chapter
De Iorio, F., Benini, L., Tacchella, N., Vantini, I. (2006). Medical Treatment of Ulcerative Colitis. In: Delaini, G.G. (eds) Inflammatory Bowel Disease and Familial Adenomatous Polyposis. Springer, Milano. https://doi.org/10.1007/88-470-0434-9_23
Download citation
DOI: https://doi.org/10.1007/88-470-0434-9_23
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0433-7
Online ISBN: 978-88-470-0434-4
eBook Packages: MedicineMedicine (R0)